Holen Sie sich die Stockscreener-App
4.85
5.43%
0.25
Handel nachbörslich:
4.84
-0.010
-0.21%
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
Class Action Filed Against Verve Therapeutics, Inc. (VERV)Oct - GuruFocus.com
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) s - GuruFocus.com
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Remind - GuruFocus.com
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com
FY2024 EPS Forecast for Verve Therapeutics Raised by Analyst - MarketBeat
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles - Investing.com India
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles By Investing.com - Investing.com UK
(VERV) On The My Stocks Page - Stock Traders Daily
What is William Blair's Forecast for VERV FY2024 Earnings? - MarketBeat
FY2024 Earnings Forecast for VERV Issued By Lifesci Capital - MarketBeat
HC Wainwright Cuts Earnings Estimates for Verve Therapeutics - MarketBeat
Analyst Scoreboard: 4 Ratings For Verve Therapeutics - Benzinga
Verve Therapeutics (NASDAQ:VERV) Price Target Lowered to $14.00 at HC Wainwright - MarketBeat
Verve Therapeutics price target raised to $32 from $29 at Canaccord - TipRanks
Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
VERVE Therapeutics stock target cut, keeps buy on trial updates By Investing.com - Investing.com UK
Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright - TipRanks
Verve Therapeutics Reports Q3 Progress and Financials - TipRanks
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates - MSN
Verve Therapeutics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
Verve Therapeutics (NASDAQ:VERV) Trading Up 10.1%Here's What Happened - MarketBeat
Verve Therapeutics reports Q3 EPS (59c), consensus (70c) - TipRanks
Verve Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Vanguard Group Inc's Strategic Reduction in Verve Therapeutics I - GuruFocus.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
VERV Deadline: VERV Investors Have Opportunity to Lead Verve The - GuruFocus.com
Deadline coming up on Oct. 28th in Lawsuit for Investors who lost - openPR
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - AccessWire
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AccessWire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire
FINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - cnhinews.com
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, - GlobeNewswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
FINAL REMINDER VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Verve Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - Business Wire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - cnhinews.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - PR Newswire
VERV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire
SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 7%Still a Buy? - MarketBeat
Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion - ForexTV.com
Verve Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback - MSN
Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – VERV - ForexTV.com
Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - AccessWire
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire
VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. - The Bakersfield Californian
VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - AccessWire
Investors who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - AccessWire
2024-10-21 | Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV | NDAQ:VERV | Press Release - Stockhouse Publishing
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):